- Collaboration to improve patient care and epidemiological monitoring in Parkway Group’s private hospitals
- QIAstat-Dx syndromic testing to provide quick and accurate detection of respiratory, gastrointestinal and central nervous system infections
- Partnership aims to reduce the burden on healthcare systems, leading to effective public health management
QIAGEN Singapore Pte. Ltd. today announced a partnership with Parkway Laboratories, one of Singapore’s leading clinical laboratories, to advance healthcare services through the installation of the QIAstat-Dx syndromic testing system in three of IHH Healthcare’s hospitals in Singapore: Gleneagles, Mount Elizabeth and Mount Elizabeth Novena hospitals.
The collaboration aims to enhance patient management by optimizing syndromic testing diagnosis and treatment with accurate pathogen identification. QIAstat-Dx, a multiplex molecular diagnostic system, employs cost-efficient, single-use cartridges with built-in sample processing and on-board reagents. Utilizing multiplex real-time PCR, it detects and differentiates between multiple pathogens, with results in about an hour, thereby providing rapid answers for the detection of a wide range of infections. The disease area panels include the QIAstat-Dx Respiratory SARS-CoV-2 Panel, QIAstat-Dx Gastrointestinal Panel, and QIAstat-Dx Meningitis/Encephalitis Panel.
The QIAstat-Dx system also provides easy-to-view cycle threshold (Ct) values and amplification curves, offering additional insights not available with end-point PCR or other techniques. By connecting to the QIAsphere, QIAstat-Dx provides Parkway Laboratories with valuable epidemiological trends to support public healthcare management.
“Our partnership with Parkway Laboratories represents a significant step forward in improving healthcare outcomes in Singapore,” said William Lin, Senior Director, Commercial Operation, APEC at QIAGEN. “By providing fast and accurate syndromic testing solutions across respiratory, gastrointestinal, and central nervous system infections, we’re enabling healthcare providers to make informed decisions quickly, potentially reducing unnecessary antibiotic use and supporting antimicrobial stewardship efforts.”
“QIAGEN’s solution contributes to Parkway Laboratories’ efforts in improving antimicrobial stewardship (AMS) through rapid diagnostics. AMS is one of IHH Healthcare’s sustainability goals, targeting the public by nurturing a healthier society” said Dr Shawn Ng, CEO of Parkway Laboratories.
The agreement expands a previous successful collaboration between QIAGEN and Parkway Laboratories for latent tuberculosis infection screening using QuantiFERON-TB Gold Plus, the leading IGRA test. This continued partnership demonstrates the ongoing commitment of both organizations to advancing healthcare diagnostics and improving patient outcomes in Singapore.
Learn more about the future of infectious disease diagnostics with syndromic testing at https://www.qiagen.com/applications/syndromic-testing
